After an extensive review, researchers said they were unsure whether the risks of prescription opioids outweighed the potential benefits for managing chronic pain.
After an extensive review, researchers said they were unsure whether the risks of prescription opioids outweighed the potential benefits for managing chronic pain.
“The efficacy of opioids and their suitability for the long-term management of chronic pain still remain very much in question….it stands in somewhat stark contrast to the clinical reality of chronic pain treatment, where rates of prescriptions have skyrocketed such that opioids are now among the most frequently prescribed medications,” wrote Kevin E. Vowles with the Department of Psychology at the University of New Mexico in Albuquerque, in the review published in the April, 2015, issue of Pain.
Vowles and his fellow researchers at the University of Washington in Seattle, Wash., and the UNM, found that the average rates of opioids misuse ranged between 21% and 29%. The rates of addiction averaged between 8% and 12%, while abuse was reported in only a single study.
Related: FDA: Final guidance on evaluation, labeling of abuse-deterrent opioids
After reviewing 38 published studies, most of which were conducted in the United States, the researchers discovered 2 primary implications. Misuse and addiction seem to be distinct patterns of problematic opioid use, and misuse seems more common than addiction. As a result, some misuses of prescription opioids may be addressed by “low-intensity intervention,” such as monthly counseling sessions, the researchers wrote.
Related: New HHS plan on opioids ups naloxone use
“If it is accurate that approximately one in four patients on opioids display patterns of opioid misuse, but not addiction, then perhaps more efficient targeting of treatment resources would be of benefit,” Vowles wrote. “Some forms of misuse, for example, may be readily addressed through relatively low-intensity methods such as education or frequent follow-up visits.”
One study in which monthly counseling sessions were provided showed that “there are alternatives available to providers who treat high-risk patients beyond simply not prescribing the medications at all,” Jowles wrote.
Read next: Babies exposed to narcotic pain relievers more likely to experience drug withdrawal syndrome
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More